Earnings
OraSure Delays Cash-Flow Breakeven To Second Half Of 2027 While Ebola Purchasing Takes Time
Revenue grew 14%, but delayed product adoption has pushed back management's timetable for ending operating cash burn.
OraSure Technologies (OSUR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Revenue grew 14%, but delayed product adoption has pushed back management's timetable for ending operating cash burn.
Earnings
HIV testing and sample-management orders lifted sales, while OraSure projects $30.0 million to $32.0 million in fourth-quarter revenue.